دورية أكاديمية
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
| العنوان: | Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. |
|---|---|
| المؤلفون: | González Del Alba A; Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain., Arranz JÁ; Medical Oncology Department, Unit of Urological and Gynecological Tumors, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Puente J; Medical Oncology Department, Hospital Universitario San Carlos, Madrid, Spain., Méndez-Vidal MJ; Oncology Department, Maimonides Institute of Medical Research (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain., Gallardo E; Oncology Department, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain., Grande E; Medical Oncology Department, GI, Endocrine and Translational Research Unit, Early Drug Development Unit-IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain., Pérez-Valderrama B; Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., González-Billalabeitia E; Medical Oncology and Hematology Department, Hospital G.U. Morales Meseguer, Murcia, Spain., Lázaro-Quintela M; Medical Oncology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain., Pinto Á; Medical Oncology Department, Hospital Universitario La Paz, Instituto de Investigación Sanitaria Hospital La Paz (IdiPAZ), Madrid, Spain., Lainez N; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain., Piulats JM; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Esteban E; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Maroto Rey JP; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., García JA; Hematology/Oncology and Urology Departments, Cleveland Clinic, Cleveland, OH, United States., Suárez C; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: csuarez@vhio.net. |
| المصدر: | Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2017 May; Vol. 113, pp. 171-190. Date of Electronic Publication: 2017 Mar 14. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Amsterdam : Elsevier Scientific Publishers Original Publication: Boca Raton, Fla. : CRC Press, 1983- |
| مواضيع طبية MeSH: | Antineoplastic Agents/*therapeutic use , Urogenital Neoplasms/*drug therapy, Antineoplastic Agents/pharmacology ; Humans ; Male ; Urogenital Neoplasms/metabolism ; Urogenital Neoplasms/pathology |
| مستخلص: | Updated information published up to 2016 regarding major advances in renal cancer, bladder cancer, and prostate cancer is here presented. Based on an ever better understanding of the genetic and molecular alterations that govern the initial pathogenic mechanisms of tumor oncogenesis, an improvement in the characterization and treatment of urologic tumors has been achieved in the past year. According to the Cancer Genome Atlas (ATLAS) project, alterations in the MET pathway are characteristics of type 1 papillary renal cell carcinomas, and activation of NRF2-ARE pathway is associated with the biologically distinct type 2. While sunitinib and pazopanib continue to be the standard first-line treatment in metastatic renal cell carcinoma of clear cell histology, nivolumab and cabozantinib are now the agents of choice in the second-line setting. In relation to urothelial bladder carcinoma, new potential molecular targets such as FGFR3, PI3K/AKT, RTK/RAS, CDKN2A, ARIDIA, ERBB2 have been identified. Response to adjuvant cisplatin-based chemotherapy appears to be related to basal, luminal, and p53-like intrinsic subtypes. A phase II study with eribulin and a maintenance phase II trial with vinflunine have shown promising results. Similarly, the use of the check point inhibitors in advanced disease is likely to revolutionize the management of patients who have progressed after cisplatin-based chemotherapy. In prostate cancer, seven mutually exclusive molecular subtypes have been identified by the TCGA project. Chemotherapy has been consolidated as a key treatment for castration-sensitive metastatic prostate cancer, and abiraterone, enzalutamide, cabazitaxel, and radium-223 remain standard therapeutic options for men with metastatic castration-resistant prostate cancer. All this progress will undoubtedly contribute to the development of new treatments and therapeutic strategies that will improve the survival and quality of life of our patients. (Copyright © 2017 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Bladder cancer; Genitourinary cancer; Molecular research; Prostate cancer; Renal cancer |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20170422 Date Completed: 20171018 Latest Revision: 20181202 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.critrevonc.2017.03.010 |
| PMID: | 28427506 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0461 |
|---|---|
| DOI: | 10.1016/j.critrevonc.2017.03.010 |